The DOI matches its Crossref record; 163 of the 163 references it cites were found in a registry or an index.
Parkinson's disease: a dual‐hit hypothesis
Open accessAbstract
Accumulating evidence suggests that sporadic Parkinson's disease has a long prodromal period during which several non-motor features develop, in particular, impairment of olfaction, vagal dysfunction and sleep disorder. Early sites of Lewy pathology are the olfactory bulb and enteric plexus of the stomach. We propose that a neurotropic pathogen, probably viral, enters the brain via two routes: (i) nasal, with anterograde progression into the temporal lobe; and (ii) gastric, secondary to swallowing of nasal secretions in saliva. These secretions might contain a neurotropic pathogen that, after penetration of the epithelial lining, could enter axons of the Meissner's plexus and, via transsynaptic transmission, reach the preganglionic parasympathetic motor neurones of the vagus nerve. This would allow retrograde transport into the medulla and, from here, into the pons and midbrain until the substantia nigra is reached and typical aspects of disease commence. Evidence for this theory from the perspective of olfactory and autonomic dysfunction is reviewed, and the possible routes of pathogenic invasion are considered. It is concluded that the most parsimonious explanation for the initial events of sporadic Parkinson's disease is pathogenic access to the brain through the stomach and nose - hence the term 'dual-hit'.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The double-hit hypothesis proposed by Hawkes et al.135 supports their theory, pointing out that a-synuclein pathology is transmitted to the midbrain through two different routes, namely, from the nasal cavity to the temporal lobe or from the stomach, followed by nasal secretions in swallowed saliva.135”
From The role of gut dysbiosis in Parkinson’s disease: mechanistic insights and therapeutic options (2021) · cites this paper as [135]
Experimental — accuracy not yet measuredIn the citing paper
“Conversely, when the α-synuclein pathology firstly occurred in the olfactory bulbs, it spread further to the brain via the olfactory tract but it also went down to the ENS and it damaged its neurons [402].”
From The Role of Microbiota-Gut-Brain Axis in Neuropsychiatric and Neurological Disorders (2021) · cites this paper as [402]
In the citing paper
“Braak and colleagues hypothesized that alpha-synuclein pathology might start in either the OB and/or in the ENS possibly by an unknown pathogen and/or environmental toxin and then progresses towards the SN and further areas in the CNS.”
From The Gut-Brain Axis in Parkinson’s Disease: Possibilities for Food-Based Therapies (2017) · cites this paper as Hawkes et al., 2007
In the citing paper
“The vagal nerve might provide a path for the spread of alpha-synuclein pathology from the ENS to the brain through the brainstem, midbrain, basal forebrain and finally the cortical areas (Braak et al., 2003;Hawkes et al., 2007)”
From The Gut-Brain Axis in Parkinson’s Disease: Possibilities for Food-Based Therapies (2017) · cites this paper as Hawkes et al., 2007
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
Self-citationThe relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.
Gibb, W. R., & Lees, A. J. (1988) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.51.6.745 · Cited by 3,481
Diagnostic Criteria for Parkinson Disease
Gelb, D. J., Oliver, E., & Gilman, S. (1999) · Archives of Neurology · doi:10.1001/archneur.56.1.33 · Cited by 2,822
Stages in the development of Parkinson’s disease-related pathology
Braak, H., Ghebremedhin, E., Rüb, U., Bratzke, H., & Del Tredici, K. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0956-9 · Cited by 2,689
Self-citationHummel, T., Sekinger, B., Wolf, S. R., Pauli, E., & Kobal, G. (1997) · Chemical Senses · doi:10.1093/chemse/22.1.39 · Cited by 2,501
Braak, H., R�b, U., Gai, W. P., & Del Tredici, K. (2003) · Journal of Neural Transmission · doi:10.1007/s00702-002-0808-2 · Cited by 1,683
Self-citationPaxinos, G., & Jürgen, K. (2004) · Cited by 1,478
Braak, H., de Vos, R. A. I., Bohl, J., & Del Tredici, K. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2005.11.012 · Cited by 1,354
Self-citationSchenck, C. H., Bundlie, S. R., & Mahowald, M. W. (1996) · Neurology · doi:10.1212/wnl.46.2.388 · Cited by 1,083
SIC Task Force appraisal of clinical diagnostic criteria for parkinsonian disorders
Litvan, I., Bhatia, K. P., Burn, D. J., Goetz, C. G., Lang, A. E., McKeith, I. G., Quinn, N. P., Sethi, K. D., Shults, C. W., & Wenning, G. K. (2003) · Movement Disorders · doi:10.1002/mds.10459 · Cited by 1,011
Research works printed but not linked: 4
- Braak H, 2005, Parkinson's Disease: Progress in Research., 1
- Sulla M, 1996, Gastric emptying time and gastric motility in patients with untreated Parkinson's disease, Mov Disord, 11, 1041
- Schenck CH, 2003, REM behavior disorder (RBD), delayed emergence of parkinsonism and/or dementia in 65% of older men initially diagnosed with idiopathic RBD, and an analysis of the minimum & maximum tonic and/or phasic electromyographic abnormalities found during REM sleep, Sleep, 26, 316
- 10.1042/bse0410139 · DOI
Cited by
Sorted by citations
Items 601–700 of 1,000
Zhou, L. N., Huang, B., Wang, J., Chau, S. W. H., Chan, J. W. Y., Zhang, J., Yu, M. W., Tsang, J. C., Li, S. X., Mok, V., et al. (2023) · Sleep Medicine · doi:10.1016/j.sleep.2023.03.007 · Cited by 10
Chronic Cocaine Use and Parkinson’s Disease: An Interpretative Model
Carbone, M. G., & Maremmani, I. (2024) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph21081105 · Cited by 10
Can α-synuclein be targeted in novel therapies for Parkinson’s disease?
Brundin, P., & Olsson, R. (2011) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.73 · Cited by 10
Levodopa pharmacokinetics -from stomach to brain : A study on patients with Parkinson’s disease
Nord, M. (2017) · Linköping University medical dissertations · doi:10.3384/diss.diva-136560 · Cited by 10
Pancreatic Polypeptide in Parkinson’s Disease: A Potential Marker of Parasympathetic Denervation
Knudsen, K., Hartmann, B., Fedorova, T. D., Østergaard, K., Krogh, K., Møller, N., Holst, J. J., & Borghammer, P. (2017) · Journal of Parkinson s Disease · doi:10.3233/jpd-171189 · Cited by 10
p27Kip1 regulates alpha-synuclein expression
Gallastegui, E., Domuro, C., Serratosa, J., Larrieux, A., Sin, L., Martinez, J., Besson, A., Morante‐Redolat, J. M., Orlando, S., Aligué, R., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24687 · Cited by 10
Initiation and Transmission of α-Synuclein Pathology in Parkinson’s Disease
Mazurskyy, A., & Howitt, J. A. (2019) · Neurochemical Research · doi:10.1007/s11064-019-02896-0 · Cited by 10
Analysis of α-Synuclein in Exosomes
Tsunemi, T., Ishiguro, Y., Yoroisaka, A., & Hattori, N. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1495-2_4 · Cited by 10
Waldron, F. M., Langerová, T., Rahmanova, A., Read, F. L., Spence, H., Roberts, K., Macleod, A. D., Pattle, S. B., Hanna, K., & Gregory, J. M. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.10.648122 · Cited by 10
Microbiota Orchestra in Parkinson’s Disease: The Nasal and Oral Maestros
Rei, N., Grunho, M., Mendes, J. J., & Fonseca, J. (2024) · Biomedicines · doi:10.3390/biomedicines12112417 · Cited by 9
Brain iron accumulation in neurodegenerative disorders: Does air pollution play a role?
George, J. V., Hornburg, K. J., Merrill, A. K., Marvin, E., Conrad, K., Welle, K. A., Gelein, R. M., Chalupa, D., Graham, U. M., Oberdörster, G., et al. (2025) · Particle and Fibre Toxicology · doi:10.1186/s12989-025-00622-z · Cited by 9
Neuroprotection in Parkinson Disease
Gonzalez‐Robles, C., Bandmann, O., & Schapira, A. H. V. (2025) · Neurology and Therapy · doi:10.1007/s40120-025-00793-z · Cited by 11
La maladie de Parkinson est-elle une maladie à prion ?
Brandel, J., Corbillé, A.-G., Derkinderen, P., & Haı̈k, S. (2015) · Revue Neurologique · doi:10.1016/j.neurol.2015.10.005 · Cited by 13
Poirier, A.-A., Côté, M., Jarras, H., Litim, N., Lamontagne‐Proulx, J., Al-Sweidi, S., Morissette, M., Lachhab, A., Pelletier, M., Paolo, T. D., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.898067 · Cited by 9
Parkinson’s disease. Focus on early stages
Катунина, Е. А., Zalyalova, Z. A., Похабов, Д. В., Ivanova, M. Z. I., & Semenova, A. M. (2023) · Neurology neuropsychiatry Psychosomatics · doi:10.14412/2074-2711-2023-3-95-103 · Cited by 12
Laursen, A.-L. S., Olesen, M. V., Folke, J., Brudek, T., Knecht, L. H., Sotty, F., Lambertsen, K. L., Fog, K., Dalgaard, L. T., & Aznar, S. (2024) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2024.103931 · Cited by 9
Elucidating the mechanisms of α-Synuclein-lipid interactions using site-directed mutagenesis
Ali, A., Holman, A. P., Rodriguez, A., Osborne, L., & Kurouski, D. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106553 · Cited by 10
Lateralized Basal Ganglia Vulnerability to Pesticide Exposure in Asymptomatic Agricultural Workers
Lewis, M. M., Sterling, N. W., Du, G., Lee, E.-Y., Shyu, G., Goldenberg, M. D. F., Allen, T. W., Stetter, C., Kong, L., Snipes, S. A., et al. (2017) · Toxicological Sciences · doi:10.1093/toxsci/kfx126 · Cited by 9
Guan, X., Wang, Y., Li, Q., Wei, M., Chen, L., & Cheng, O. (2018) · Neurological Sciences · doi:10.1007/s10072-018-3502-3 · Cited by 10
An Infection Hypothesis of Parkinson’s Disease
Karpenko, M. N., Muruzheva, Z. M., Pestereva, N. S., & Ekimova, I. V. (2019) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-019-00769-1 · Cited by 9
In vivo modeling of prodromal stage of Parkinson’s disease
Cerri, S., & Blandini, F. (2020) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2020.108801 · Cited by 9
Ding, Y., Li, Y., Chhetri, G., Peng, X., Wu, J., Wang, Z., Zhao, B., Zhao, W., & Li, X. (2021) · Cells · doi:10.3390/cells10040746 · Cited by 9
Deciphering the prion-like behavior of pathogenic protein aggregates in neurodegenerative diseases
Yoshida, S., & Hasegawa, T. (2022) · Neurochemistry International · doi:10.1016/j.neuint.2022.105307 · Cited by 9
Donepezil for Constipation in Lewy Body Diseases: Four Case Studies
Lepkowsky, C. M. (2017) · Activitas Nervosa Superior · doi:10.1007/s41470-017-0004-1 · Cited by 9
Different Prion Conformers Target the Olfactory Pathway in Sporadic Creutzfeldt–Jakob Disease
Zanusso, G., Ferrari, S., Benedetti, D., Sbriccoli, M., Rizzuto, N., & Monaco, S. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.03905.x · Cited by 9
Olfactory Dysfunction as a Window Into the Heterogeneity of Parkinson Disease
Sun, Y., Na, H. K., Yoon, S. H., Vo, Q. P., Park, C. W., Lee, J. H., Choi, Y. Y., Yoo, H. S., Sohn, Y. H., Lyoo, C. H., et al. (2025) · European Journal of Neurology · doi:10.1111/ene.70404 · Cited by 8
Maintenance and Decline of Neuronal Lysosomal Function in Aging
Zhong, R., & Richardson, C. E. (2025) · Cells · doi:10.3390/cells14241976 · Cited by 8
Food Contamination: An Unexplored Possible Link between Dietary Habits and Parkinson’s Disease
Caioni, G., Cimini, A., & Benedetti, E. (2022) · Nutrients · doi:10.3390/nu14071467 · Cited by 9
Yin, D. X., Toyoda, H., Nozaki, K., Satoh, K., Katagiri, A., Adachi, K., Kato, T., & Satō, H. (2022) · Journal of Parkinson s Disease · doi:10.3233/jpd-223273 · Cited by 8
Disease mechanisms as subtypes: Microbiome
Bonvegna, S., & Cilia, R. (2023) · Handbook of clinical neurology · doi:10.1016/b978-0-323-85555-6.00006-0 · Cited by 8
Infectious Microorganisms Seen as Etiologic Agents in Parkinson’s Disease
Stroe, A. Z., Jurja, S., MEHEDINTI, M. C., Stoica, A.-M., Chita, D. S., Stuparu, A. F., & Axelerad, A. D. (2023) · Life · doi:10.3390/life13030805 · Cited by 8
Xing, T., Nanni, G., Burkholder, C. R., Browning, K. N., & Travagli, R. A. (2023) · The Journal of Physiology · doi:10.1113/jp284238 · Cited by 10
Bagnoli, E., Trotier, A., McMahon, J. M., Quinlan, L. R., Biggs, M. J. P., Pandit, A. S., & FitzGerald, U. (2023) · The FASEB Journal · doi:10.1096/fj.202301253r · Cited by 8
Gastrointestinal dysmotility in rodent models of Parkinson’s disease
Pellegrini, C., & Travagli, R. A. (2024) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00225.2023 · Cited by 8
Pain characterization in patients with Parkinson's disease
Nogueira, A. C. R., Pereira, K. C., Rodrigues, V. F., Alves, D. D. P. A., Marques, J. B., Monteiro, E. R., & de Jesus, I. R. T. (2024) · Pain Practice · doi:10.1111/papr.13352 · Cited by 8
Unveiling Parkinson’s disease through biomarker research: current insights and future prospects
Çelik, N. D., Özben, S., & Özben, T. (2024) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2024.2331471 · Cited by 8
Totsune, T., Baba, T., Hasegawa, T., & Takeda, A. (2025) · Movement Disorders · doi:10.1002/mds.30174 · Cited by 8
Olfactory Dysfunction and Its Relationship With Clinical Features of Parkinson's Disease
Zhou, Y., He, R., Zhao, Y., He, Y., Hu, Y., Sun, Q., Xu, Q., Tan, J., Yan, X., Tang, B., et al. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.526615 · Cited by 8
Fibromiyalji Sendromu ile Bağırsak Mikrobiyotası Arasındaki İlişkinin Araştırılması
Albayrak, B., Süsgün, S., Küçükakkaş, O., Akbaş, F., Yabacı, A., & Özçelik, S. (2021) · Mikrobiyoloji Bulteni · doi:10.5578/mb.20219903 · Cited by 9
An Overview of Gastrointestinal Dysfunction in Parkinsonian Syndromes
Talman, L. S., & Safarpour, D. (2023) · Seminars in Neurology · doi:10.1055/s-0043-1771461 · Cited by 8
Ratajska, A. M., Etheridge, C. B., Lopez, F. V., Kenney, L. E., Rodriguez, K., Schade, R. N., Gertler, J., & Bowers, D. (2023) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/08919887231204542 · Cited by 9
Nutrition and Gastrointestinal Health as Modulators of Parkinson’s Disease
Rasmussen, H. E., Piazza, B., Forsyth, C. B., & Keshavarzian, A. (2014) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-319-06151-1_11 · Cited by 9
Rare coding SNP in DZIP1 gene associated with late-onset sporadic Parkinson's disease
Valente, A. X. C. N., Shin, J. H., Sarkar, A., & Gao, Y. (2012) · Scientific Reports · doi:10.1038/srep00256 · Cited by 8
Mitral cells and the glucagon‐like peptide 1 receptor: The sweet smell of success?
Bagnoli, E., & FitzGerald, U. (2018) · European Journal of Neuroscience · doi:10.1111/ejn.14115 · Cited by 8
Chung, S. J., Yoo, H. S., Lee, Y. H., Sohn, Y. H., Ye, B. S., Cha, J., & Lee, P. H. (2020) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2020.10.038 · Cited by 8
The intestinal luminal sources of α-synuclein: a gastroenterologist perspective
Lerner, A. (2021) · Nutrition Reviews · doi:10.1093/nutrit/nuab024 · Cited by 9
The second brain in Parkinson’s disease: fact or fantasy?
Yemula, N., Njoku, P., & Takyi, J. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.332144 · Cited by 8
A colonic biomarker of Parkinson's disease?
Olanow, C. W. (2012) · Movement Disorders · doi:10.1002/mds.25067 · Cited by 8
Gut-brain nexus: Mapping multimodal links to neurodegeneration at biobank scale
Shafieinouri, M., Hong, S., Lee, P. S., Grant, S. M., Khani, M., Dadu, A., Schuh, A. F. S., Makarious, M. B., Sandon, R., Simmonds, E., et al. (2025) · Science Advances · doi:10.1126/sciadv.adu2937 · Cited by 8
Alterations of Gut Microbiota and Microbial Metabolites in Parkinson’s Disease: A Systematic Review
Davoody, S., Vakili, K. G., Jazi, K., Fathi, M., Heidari‐Foroozan, M., Mofidi, S. A., Taremi, M., Taherkhani, A., Azadnajafabad, S., Hojjatipour, F., et al. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05598-7 · Cited by 7
Muhammad, B., Li, H., Gu, Y., Xue, S., Gao, Y., Xu, Z., Fang, X., Ding, H., Wu, F., Geng, D., et al. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15886 · Cited by 7
Wang, H., Wang, Z., Tian, J., Ma, D., & Shi, C. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1294879 · Cited by 7
Wang, Z., Ma, D., Li, M., Liang, Y., Hu, Z., Li, S., Zuo, C., Hao, C., Feng, Y., Guo, M., et al. (2024) · npj Parkinson s Disease · doi:10.1038/s41531-024-00691-5 · Cited by 7
Parkinson’s disease with hyposmia and dysautonomia: does it represent a distinct subtype?
Yoon, S. H., You, D. H., Na, H. K., Kang, S., Baik, K., Park, M., Lyoo, C. H., Sohn, Y. H., & Lee, P. H. (2024) · Journal of Neurology · doi:10.1007/s00415-024-12332-1 · Cited by 7
Experimental Parkinson models and green chemistry approach
AKYAZI, Ö., Korkmaz, D., & Cevher, Ş. C. (2024) · Behavioural Brain Research · doi:10.1016/j.bbr.2024.115092 · Cited by 7
Alpha-synuclein pathology enhances peripheral and CNS immune responses to bacterial endotoxins
Hartke, A.-S., Schreiber, C. S., Lau, K., Wiesweg, I., Waltl, I., Kalinke, U., Richter, F., & Käufer, C. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106773 · Cited by 8
Marzookian, K., Aliakbari, F., Hourfar, H., Sabouni, F., Otzen, D. E., & Morshedi, D. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.140387 · Cited by 7
Clinical and Dopamine Depletion Patterns in Hyposmia- and Dysautonomia-Dominant Parkinson’s Disease
Yoo, H. S., Lee, S., Jeong, S. H., Ye, B. S., Sohn, Y. H., Yun, M., & Lee, P. H. (2021) · Journal of Parkinson s Disease · doi:10.3233/jpd-212747 · Cited by 7
Microorganisms associated with increased risk of Parkinson’s disease
Fernández‐Espejo, E. (2022) · Neurología (English Edition) · doi:10.1016/j.nrleng.2020.08.023 · Cited by 7
COVID-19 and Parkinson’s Disease: Possible Links in Pathology and Therapeutics
Tiwari, S., Yadav, N., & Singh, S. (2022) · Neurotoxicity Research · doi:10.1007/s12640-022-00540-4 · Cited by 7
A role of human microbiota in the development of neurodegenerative diseases
Epishina, I. V., & Budanova, E. V. (2022) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro202212210157 · Cited by 8
α‐Synuclein decoy peptide protects mice against α‐synuclein‐induced memory loss
Guo, Q., Kawahata, K., Jia, W., Wang, H., Cheng, A., Yabuki, Y., Shioda, N., & Fukunaga, K. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14120 · Cited by 9
Anti-Inflammatory Effect of Traditional Chinese Medicine on the Concept of Mind-Body Interface
Tsai, S.-T., Nithiyanantham, S., Satyanarayanan, S. K., & Su, K. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-981-19-7376-5_19 · Cited by 7
Loosen, S. H., Yaqubi, K., May, P., Konrad, M., Gollop, C., Luedde, T., Kostev, K., & Roderburg, C. (2023) · Life · doi:10.3390/life13040897 · Cited by 7
Structural disorder and the loss of RNA homeostasis in aging and neurodegenerative disease
Gray, D. A., & Woulfe, J. (2013) · Frontiers in Genetics · doi:10.3389/fgene.2013.00149 · Cited by 8
Beekes, M. (2021) · Viruses · doi:10.3390/v13071394 · Cited by 7
In vitro neurotoxicity of salsolinol is attenuated by the presynaptic protein α-synuclein
Gonçalves, P. D. C., Cerqueira, E. C., Cortines, J. R., de Souza, T. L. F., Romão, L. F., & Follmer, C. (2018) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2018.08.022 · Cited by 7
Gastrointestinal dysfunction in Parkinson's disease
Timpka, J., & Odin, P. (2021) · International review of movement disorders · doi:10.1016/bs.irmvd.2021.07.004 · Cited by 7
Veasey, S. C. (2009) · Contemporary clinical neuroscience · doi:10.1007/978-1-60327-342-8 · Cited by 7
An archaeal compound as a driver of Parkinson’s disease pathogenesisPreprint
Wilmes, P., Trezzi, J., Aho, V. T. E., Jäger, C., Schade, S., Janzen, A., Hickl, O., Kunath, B. J., Thomas, M. H., Schmit, K. J., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1827631/v1 · Cited by 7
The ketogenic diet in Parkinson’s disease: a potential therapeutic strategy
Pokora, B., Pokora, K., Binienda, A., & Fichna, J. (2025) · Pharmacological Reports · doi:10.1007/s43440-025-00799-2 · Cited by 9
A Review on the Nasal Microbiome and Various Disease Conditions for Newer Approaches to Treatments
Sarkar, S., Routhray, S., Ramadass, B., & Parida, P. K. (2022) · Indian Journal of Otolaryngology and Head & Neck Surgery · doi:10.1007/s12070-022-03205-y · Cited by 7
Natalello, A., Brocca, S., Ponzini, E., Santambrogio, C., & Grandori, R. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2810266 · Cited by 6
Ozawa, M., Morishima, R., Shimizu, T., & Takahashi, K. (2024) · Neurophysiologie Clinique · doi:10.1016/j.neucli.2024.102956 · Cited by 6
Zheng, J., Shi, W., Yang, Q., Huang, J., Shen, J., Yin, L., Zhang, P., Zhang, S., Yang, M., Qian, A., et al. (2024) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2024.06.016 · Cited by 6
Hallbeck, M., Ekmark‐Lewén, S., Kahle, P. J., Ingelsson, M., & Reyes, J. F. (2024) · iScience · doi:10.1016/j.isci.2024.111448 · Cited by 6
Omejc, N., Stankovski, T., Peskar, M., Kalc, M., Manganotti, P., Gramann, K., Džeroski, S., & Marušič, U. (2025) · IEEE Transactions on Neural Systems and Rehabilitation Engineering · doi:10.1109/tnsre.2025.3527578 · Cited by 6
Evidence for cross-hemispheric preconditioning in experimental Parkinson’s disease
Weilnau, J. N., Carcella, M. A., Miner, K. M., Bhatia, T. N., Hutchison, D. F., Pant, D. B., Nouraei, N., & Leak, R. K. (2017) · Brain Structure and Function · doi:10.1007/s00429-017-1552-6 · Cited by 6
Disease modifying therapies for Parkinson's disease: Novel targets
Vijiaratnam, N., & Foltynie, T. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108839 · Cited by 6
Magalhães, F. E. X., da Silva, V. N. C., Fernandes, J. R. N., de Oliveira, A. T., Fernandes, T. R. S., & Teixeira, S. S. (2022) · Research Society and Development · doi:10.33448/rsd-v11i7.29762 · Cited by 6
van der Keylen, P., Garreis, F., Steigleder, R., Sommer, D. D., Neuhuber, W., & Wörl, J. (2016) · Histochemistry and Cell Biology · doi:10.1007/s00418-015-1403-6 · Cited by 6
Psychiatric, nonmotor aspects of Parkinson's disease
Müller, T. H., Gerlach, M., Youdim, M. B. H., & Riederer, P. F. (2012) · Handbook of clinical neurology · doi:10.1016/b978-0-444-52002-9.00028-0 · Cited by 6
Neurodegenerative Disease Conditions and Genomic Treatment for Better Health
Badhe, R. V., Chejara, D. R., Kumar, P., Choonara, Y. E., & Pillay, V. (2018) · Springer eBooks · doi:10.1007/978-981-10-7506-3_15 · Cited by 6
Is either anosmia or constipation associated with cognitive dysfunction in Parkinson’s disease?
Sheng, M.-Z., Fang, T.-C., Chen, Y.-H., Chang, M., Yang, C., & Lin, C. (2021) · PLoS ONE · doi:10.1371/journal.pone.0252451 · Cited by 6
Macroscopic diagnostic clue for parkinsonism
Yoshida, M., Akagi, A., Miyahara, H., Riku, Y., Ando, T., Ikeda, T., Yabata, H., Moriyoshi, H., Koizumi, R., & Iwasaki, Y. (2022) · Neuropathology · doi:10.1111/neup.12853 · Cited by 6
Ting, S.-J. (2017) · The Chinese Journal of Physiology · doi:10.4077/cjp.2017.baf449 · Cited by 6
Olfactory Dysfunction as a Clinical Marker of Early Glymphatic Failure in Neurodegenerative Diseases
Sánchez‐Benavides, G., Iranzo, Á., Grau‐Rivera, O., Giraldo, D. M., & Buongiorno, M. (2025) · Diagnostics · doi:10.3390/diagnostics15060719 · Cited by 6
Ilie, O., Văcărean-Trandafir, I.-C., Amărandi, R.-M., Nita, I.-B., Dobrin, R., Doroftei, M., Ivanov, I.-C., Săvuţă, G., Kirov, B., & Doroftei, B. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1654995 · Cited by 6
Brown, R. E. (2022) · The EuroBiotech Journal · doi:10.2478/ebtj-2022-0008 · Cited by 5
The Role of Helicobacter pylori and Small Intestinal Bacterial Overgrowth in Parkinson's Disease
Justich, M. B., Rojas, O. L., & Fasano, A. A. (2023) · Seminars in Neurology · doi:10.1055/s-0043-1771468 · Cited by 5
Vingeliene, S., Hiyoshi, A., Lentjes, M. A. H., Brummer, R. J., Fall, K., & Montgomery, S. (2024) · Brain Communications · doi:10.1093/braincomms/fcae098 · Cited by 5
Role of Inflammation and the NF-κB Signaling Pathway in Hirschsprung’s Disease
Elkrewi, E. Z., Abdulqader, A. A. A., Khasanov, R., Maas‐Omlor, S., Wessel, L. M., Boettcher, M., Schäfer, K., & Tapia-Laliena, M. Á. (2024) · Biomolecules · doi:10.3390/biom14080992 · Cited by 5
Bidirectional relationship between olfaction and Parkinson’s disease
Kim, J. J., Bandrés‐Ciga, S., Heilbron, K., Aslibekyan, S. W., Auton, A., Babalola, E., Bell, R. K., Bielenberg, J., Bowes, J., Bryc, K., et al. (2024) · npj Parkinson s Disease · doi:10.1038/s41531-024-00838-4 · Cited by 5
From blood vessels to brain cells: Connecting the circulatory system and Parkinson's disease
Olaoye, O. J., Farrow, S. L., Nyaga, D. M., Cooper, A. A., & O'Sullivan, J. M. (2025) · Journal of Parkinson s Disease · doi:10.1177/1877718x241308168 · Cited by 6
Microorganismos relacionados con un mayor riesgo de presentar la enfermedad de Parkinson
Fernández‐Espejo, E. (2020) · Neurología · doi:10.1016/j.nrl.2020.08.020 · Cited by 5
Vacca, L., Proietti, S., Bravi, D., Radicati, F. G., & Stocchi, F. (2021) · Neurological Sciences · doi:10.1007/s10072-021-05342-8 · Cited by 5
Ultrasound imaging of vagus nerves in patients with Parkinson's disease
Чечеткин, А. О., Николаевна, М. А., Fedotova, E. Y., & Illarioshkin, S. N. (2021) · Bulletin of Russian State Medical University · doi:10.24075/brsmu.2021.054 · Cited by 5
Litvinenko, I., & Lobzin, V. Y. (2022) · Advances in Gerontology · doi:10.1134/s2079057022040117 · Cited by 5
Dietary Restriction against Parkinson’s Disease: What We Know So Far
Wang, Z., Cui, Y., Wen, L., Yu, H., Feng, J., Yuan, W., & He, X. (2022) · Nutrients · doi:10.3390/nu14194108 · Cited by 5
Anderson–Fabry Disease: A New Piece of the Lysosomal Puzzle in Parkinson Disease?
Zedde, M., Pascarella, R., Cavallieri, F., Pezzella, F. R., Grisanti, S., Fonzo, A. D., & Valzania, F. (2022) · Biomedicines · doi:10.3390/biomedicines10123132 · Cited by 5
Metadata
- Authors
- Hawkes, C. H., Del Tredici, K., & Braak, H.
- Affiliations
- Queen's Hospital (GB)
- Goethe University Frankfurt (DE)
- Corresponding author
- Hawkes, C. H.
- Venue
- Neuropathology and Applied Neurobiology
- Publisher
- Wiley
- Published
- 2007-10-24
- Volume
- 33
- Issue
- 6
- Pages
- 599-614
- ISSN
- 0305-1846 (ISSN-L)
- 1365-2990
- PMC
- PMC7194308
- OpenAlex
- W2105047187
- Cited by
- 1,021
- References
- 163
- Citations by year
- 2026: 35 · 2025: 59 · 2024: 87 · 2023: 82 · 2022: 104 · 2021: 117 · 2020: 83 · 2019: 59 · 2018: 49 · 2017: 63 · 2016: 41 · 2015: 33 · 2014: 32 · 2013: 40 · 2012: 33
- FWCI
- 2.90
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Neuropathology and Applied Neurobiology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Deutsche Forschungsgemeinschaft
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Parkinson's disease, neurotropic viruses, olfactory dysfunction, Lewy bodies, vagal dysfunction, sleep disorder, olfactory bulb, submucosal plexus, vagus nerve, substantia nigra, prodromal Parkinson's disease, viral pathogenesis
- MeSH terms
- Animals, Olfaction Disorders, Gastrointestinal Diseases, Heart Diseases, Humans, Models, Neurological, Parkinson Disease, Sleep Wake Disorders, Virus Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
